Methods for detecting lung cancer
OwnerPaul PAGANO, Daniel GRAMAJO-LEVENTON +4inventors
InventorsPaul PAGANO, Daniel GRAMAJO-LEVENTON, Rebecca REED, Shahram TAHVILIAN, Lara BADEN, Ashley BROWN
Life of this patent
Estimating the term…
Loading patent…
OwnerPaul PAGANO, Daniel GRAMAJO-LEVENTON +4inventors
InventorsPaul PAGANO, Daniel GRAMAJO-LEVENTON, Rebecca REED, Shahram TAHVILIAN, Lara BADEN, Ashley BROWN
Estimating the term…
The present disclosure provides a method for of determining the level of circulating tumor cells (CTCs) in a sample having blood cells from a patient comprising obtaining a test sample from a human subject; enriching circulating tumor cells (CTC); hybridizing the enriched cells in the sample with labeled nucleic acid probes that hybridize to regions of chromosomal DNA; evaluating the signal pattern for the selected cells by detecting fluorescence in situ hybridization from cells; detecting CTCs based on the pattern of hybridization to the labeled nucleic acid probes to said selected cells; and identifying the subject at risk for the development of lung cancer when the number of CTC per sample is above a predetermined cutoff value.--
A method for identifying a subject at risk for the development of lung cancer comprising:
A method for identifying a subject at risk for the development of lung cancer comprising:
A method of evaluating cancer in a subject comprising determining the level of circulating tumor cells (CTCs) in a sample containing blood cells from the patient by the method of any one of the preceding claims, wherein a higher level of CTCs in the sample, as compared to a control or predetermined number of CTCs from a non-aggressive form of cancer, is indicative of an aggressive form of cancer and/or a poor cancer prognosis.
A method of staging cancer in a subject comprising determining circulating tumor cells (CTC) in a sample containing blood cells from the subject by the method of any one of the preceding claims, wherein a higher level of CTCs in the sample as compared to a predetermined control for a given stage is indicative of a more advanced stage of cancer, and a lower level of CTCs in the sample as compared to a control for a given stage is indicative of a less advanced stage of cancer.
Dependencies are inferred from the claim text.